Benralizumab Matches Mepolizumab for Rare Vasculitis
WASHINGTON — Treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), the randomized MANDARA trial showed. Among 140 patients receiving standard therapy, the adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group, […]
Benralizumab Allows Inhaled Corticosteroid Taper for Asthma Patients
MILAN — Benralizumab (Fasenra) allowed patients with severe eosinophilic asthma to reduce inhaled corticosteroid (ISC) use without compromising control, the SHAMAL phase IV randomized trial found. After 32 weeks, 92% of patients on the monoclonal antibody with planned tapering from high-dose ICS plus formoterol were able to reduce their use, reported David J. Jackson, MD, […]